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Health Effects of
Hexachlorobenzene and the
TEF Approach
In her paper, van Birgelen (1) argued that
hexachlorobenzene (HCB) should be dassified
asadioxin-like compound, withatoxicequiva-
lency factor (TEF) value of0.0001. By doing
this, HCBcouldadd 10-60% to thetotal toxic
equivalents (TEQs) in human milk samples in
most countries. To indude a compound in the
TEF concept, the following criteriaare used: a)
the compound mustshowastructural relation-
ship to polychlorinated dibenzo-p-dioxins or
polychlorinated dibenzofurans; b) the com-
pound must bind to thearylhydrocarbon (Ah)
receptor; c) the compound must elicit Ah
receptor-mediated biochemical and toxic
responses; and d) the compound must be per-
sistent and accumulate in the food chain (2).
van Birgelen (1) also referred to these criteria.
In respect to the toxic responses, one can
question the validity of using a TEF
approach for HCB, because the most basic
assumption for this concept is that the com-
bined effects are dose or concentration addi-
tive (3). The dioxin-like effects for HCB
mentioned by van Birgelen (1) are reduction
in reproduction, splenomegaly, increase in
mortality, neurologic alterations, teratologic
effects, and immunotoxic effects. Although
TCDD and HCB share target organs oftoxi-
city, the effects produced in these systems or
organs do differ:
*Laboratory animals that are lethally exposed
to TCDD die following a wasting disease
that is not seen in HCB poisoning
*Neurotoxic effects such as tremors are typi-
cal after HCB exposure in rodents and
birds (4) but are not observed after TCDD
poisoning (5)
*Thymic atrophy and suppression of thy-
mus-dependent immunity is a hallmark of
TCDD toxicity observed in all species
investigated (6), whereas the immunotoxici-
ty of HCB is species-dependent: this is
characterized in rats and in humans by
splenomegaly, enlarged lymph nodes, and
enhancement of parameters of specific
immunity, and in the mouse bysuppression
ofmost immune responses (4)
*Target organs for the carcinogenic actions
ofHCB and TCDD are different; only the
liver and thyroid are target organs for both
compounds (5,7)
*Edema formation, not mentioned by van
Birgelen (1), is a pathology typically caused
by TCDD in some species, which includes
subcutaneous edema, ascites, and
hydropericardium in the chicken (5)
* Chloracne is a specifically characteristic skin
disease attributed to human exposure to
TCDD-like compounds, whereas the cuta-
neous lesions caused by HCB poisoning are
hirsutism and bullous lesions, usually in
sun-exposed skin areas; these skin lesions in
victims ofHCB poisoning have been attrib-
uted to the porphyrogenic activity of HCB
(4,4.
Furthermore, for the toxic effects of HCB
mentioned above (which differ largely from
those induced by TCDD, although in the
same target organs), there are no available
data that show these effects to beAh receptor
mediated. These considerations do notjustify
the TEF approach as defined by Ahlborg et
al. (2) for HCB.
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Hexachlorobenzene: van
Birgelen's Response
I appreciate Vos's comments about the inclu-
sion of HCB in the TEF concept, in refer-
ence to my paper on the dioxin-like proper-
ties ofHCB (1). Voscorrecdy points out that
various effects of HCB are not identical to
those ofTCDD. However, HCB has some
properties that are typical for dioxin-like
compounds. These indude binding to theAh
receptor and induction of cytochrome
P4501A. In addition, HCB has been shown
to bioaccumulate. These factors are a prereq-
uisite for including a compound in the TEF
concept, which compares the potency of a
dioxin-like compound to TCDD. TEFs are
consensus values based on available data on
relative potency values for specific com-
pounds (4. TEF values are used to estimate
the total dioxin activity in environmental and
human samples by multiplying the TEF
value by the concentration of each com-
pound, leading to a certain number ofTEQs
for each compound. The summation of all
TEQs in a certain mixture expresses the total
dioxin activity of the mixture. Based on the
binding affinity of HCB to the Ah receptor
and on in vitro cytochrome P4501A induc-
tion and porphyrin accumulation, I estimated
a relativepotency of0.0001 for HCB (1).
Because HCB also has other properties,
such as being a mixed-type cytochrome P450
inducer, effects that are not typical for
TCDD are to be expected. Mono-ortho-sub-
stituted polychlorinated biphenyls (PCBs) are
also mixed-type cytochrome P450 inducers;
they have biologic effects that differ from
those produced by TCDD, and yet they are
included in the TEF concept. These PCBs
induce both cytochrome P4501A and
P4502B activities, which are also induced by
HCB. Since mono-ortho-substituted PCBs
are included in the TEF concept, HCB
should also be included.
However, the database used to derive a
TEF value for HCB is rather weak because
there are currently no in vivo data that com-
pare HCB to TCDD. In order to produce
these data, the National Toxicology Program
(NTP) has initiated subchronic studies that
can be used to derive in vivo relative potency
values. These studies will include measure-
ment ofthe activities ofcytochrome P4501A1
and P4501A2, and determination of tissue
concentrations to estimate the total body bur-
den. Inaddition, the NTP has initiated a con-
tinuous breeding reproduction study which
indudes end points that have been shown to
beaffected byTCDD and thatcurrently drive
risk assessment ofdioxin-like compounds (3).
This information should be useful in deriving
atolerable dailyintakeforHCB.
In conclusion, a TEF value for HCB is
warranted on the basis ofproperties that are
similar to other compounds which are
included in the TEF concept. This TEF
value should be based on in vivostudies to be
most useful in the estimation of the total
TEQ in human and environmental samples.
By excluding HCB from the TEF concept,
the total dioxin activity in human and envi-
ronmental samples would be underestimated,
especially inhuman breast milk (1).
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